研究环孢菌素A对再障病患骨髓细胞Fas表达及凋亡率的影响

Research on the Influence of Cyclosporin A to Patients with Aplastic Anemia's Marrow Cells Fas Expression and Apoptosis Rate

目的:研究环孢菌素A(CsA)对再生障碍病患骨髓细胞Fas表达及凋亡率的影响。方法:从2010年2月-2013年2月,本院共计48例病患被确诊为再障。以数字法随机分成观察组24例和对照组24例,对照组以注射用丹参治疗,观察组在此基础上另以CsA治疗。对比两组疗效,分析CsA对于再障病患骨髓Fas表达情况和对MNC有关凋亡率影响。结果:观察组总有效率为83.33%(20/24),显著高于对照组的37.50%(9/24),比较差异有统计学意义(P<0.05)。两组在治疗前后CD34+Fas+的细胞百分率相比,差异无统计学意义。观察组病患骨髓CD34-细胞的Fas表达和对照组相比,差异无统计学意义。观察组治疗后MNC有关凋亡率为(2.27±0.74)%,显著低于治疗前的(6.58±2.33)%,以及对照组治疗后的(2.92±1.20)%,比较差异均有统计学意义(P<0.05)。结论:细胞Fas异常表达和再障发病情况有一定联系,以CsA治疗再障病患,可明显降低其骨髓MNC凋亡率,疗效显著,值得临床推荐。

Objective：To study the influence of Cyclosporin A（CsA）to patients with aplastic anemia’s marrow cells Fas expression and apoptosis rate. Method：From February 2010 to February 2013,in our hospital a total of 48 patients were diagnosed with aplastic anemia,who were digital randomly divided into observation group（24 cases）and control group（24 cases）. The control group was treated with salvia injection,the observation group on the basis of it was treated with CsA. To compare the curative effect of the two groups,and analyze the influence of CsA to patients with aplastic anemia’s marrow cells Fas expression and apoptosis rate. Result：The total effective rate of the observation group was 83.33%（20/24）,which was significantly higher than that of the control group 37.50%（9/24）,and difference was statistically significant（P〈0.05）. To compare both the two groups before and after treatment of CD34＋ Fas＋ cell percentage,the difference was not statistically significant. To compare the observation group’s Fas expression of bone marrow CD34-cells with the control group,the difference was not statistically significant. The observation group after treatment’s MNC apoptosis rate was（2.27±0.74）%,which was significantly lower than（6.58±2.33）% before treatment,and（2.92±1.20）%of the control group after treatment,the differences were statistically significant（P〈0.05）. Conclusion：The abnormal expression of Fas has some contact with the incidence of aplastic anemia. Using CsA to treat patients with aplastic anemia can significantly reduce the bone marrow MNC apoptosis rate. It has a significant effect and is worthy of recommendation.